Dualitas launches with $65 million Series A

California, USA-based Dualitas yesterday launched from stealth with a $65 million Series A financing co-led by Versant Ventures and Qiming Venture Partners USA, and participation from founding investor SV Health Investors and new strategic investors Chugai Venture Fund, Eli Lilly (NYSE: LLY) and Alexandria Venture Investments.

The company said the funds will be used to advance a portfolio of next-generation bispecific antibodies (BsAbs). Dualitas has identified two lead candidates, DTX-103 for allergic disease and DTX-102 for autoimmune disease - specifically rheumatoid arthritis - and is looking for partnerships for diseases beyond immunity and inflammation.

Unlike traditional, typically narrow, bispecific discovery approaches that pursue incremental gain, DualScreen operates at combinatorial scale to functionally identify candidates with highly differentiated activity, including through cell-surface proximity mechanisms, across the unexplored co-target space.